Novo Nordisk Sued By Woman Claiming Negative Ozempic Side Effects

New Analysis Suggests Long-Term Effectiveness for Wegovy Users

New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users . NBC reports that patients taking Novo Nordisk's obesity treatment maintain an average of 10% weight loss over four years. The news potentially boosts the drugmaker's push for Wegovy to be covered by insurers and governments. . The company submitted long-term findings at the European Congress on Obesity in Venice, Italy. . This is the longest study we’ve conducted so far of semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC. We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC. According to another analysis published by the drugmaker, approximately 17% of trial participants stopped using the treatment due to side effects like nausea. . The costly treatment ranges from $200 to nearly $2,000 per month in the ten countries where the drug is available. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. Rival Eli Lilly launched its drug Zepbound in the United States in December of 2023. . Neither drugmaker has managed to produce enough of the treatment to meet surging demand

Latest Weight-Loss Drug Faces Shortages

Latest Weight-Loss Drug , Faces Shortages . The United States Food and Drug Administration (FDA) says that high demand has left the latest weight-loss drug, Zepbound, in short supply. 'Newsweek' reports that the Eli Lilly product is expected to experience limited availability through Q2 of 2024 as surging demand has outpaced the manufacturer's expectations. We have experienced an unparalleled surge in demand for our type 2 diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'. We recognize this situation may cause a disruption in peoples' treatment regimens and are working with purpose and urgency to help meet the surge in demand, Eli Lilly spokesperson, via 'Newsweek'. The FDA said that Novo Nordisk's weight-loss drug, Wegovy, is also experiencing a widespread supply shortage with no end in sight for the drug's limited availability. By the year 2030, 'Newsweek' reports that the weight-loss drug market is expected to grow to about $100 billion. We expect our investments in manufacturing and supply capacity to progressively increase production of our medicines throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'. Over the past year, manufacturer Eli Lilly has already seen share prices rise over 102%. The company has announced plans to expand operations to meet increased demand for its incretin products which are used in the firm's diabetes treatments. . Incretin mimics gut hormones that regulate blood sugar while also suppressing appetite